Parazoanthoxanthin A blocks Torpedo nicotinic acetylcholine receptors

Chemico-Biological Interactions

Volumn 187, Issue 1-3, 2010, Pages 384-387

  Rozman, Klara Bulc ^a   Araoz, Romulo ^b   Sepčić, Kristina ^c   Molgo, Jordi ^b   Šuput, Dušan ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b LABORATOIRE DE NEUROBIOLOGIE CELLULAIRE ET MOLÉCULAIRE   (France)

^c UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Acetylcholinesterase inhibitor; Parazoanthoxanthin A; Torpedo nicotinic acetylcholine receptor; Xenopus oocyte

Indexed keywords

ACETYLCHOLINE; CHOLINESTERASE INHIBITOR; NICOTINIC RECEPTOR; PARAZOANTHOXANTHIN A; TUBOCURARINE CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CHANNEL GATING; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; FEMALE; MEMBRANE CURRENT; NONHUMAN; OOCYTE; TORPEDO; XENOPUS LAEVIS;

XENOPUS LAEVIS;

EID: 77955519300     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2010.03.016     Document Type: Article

References (23)

1. Arias H.R., Bhumireddy P., Bouzat C. Molecular mechanisms and binding site locations for noncompetitive antagonists of nicotinic acetylcholine receptors. Int. J. Biochem. Cell Biol. 2006, 38(8):1254-1276.
2. Hucho F. The nicotinic acetylcholine receptor and its ion channel. Eur. J. Biochem. 1986, 158(2):211-226.
3. Taly A., Corringer P.J., Guedin D., Lestage P., Changeux J.P. Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system. Nat. Rev. Drug Discov. 2009, 8(9):733-750.
4. Rose J.E. Multiple brain pathways and receptors underlying tobacco addiction. Biochem. Pharmacol. 2007, 74(8):1263-1270.
5. Dwoskin L.P., Crooks P.A. A novel mechanism of action and potential use for lobeline as a treatment for psychostimulant abuse. Biochem. Pharmacol. 2002, 63(2):89-98.
6. Rollema H., Coe J.W., Chambers L.K., Hurst R.S., Stahl S.M., Williams K.E. Rationale, pharmacology and clinical efficacy of partial agonists of alpha4beta2 nACh receptors for smoking cessation. Trends Pharmacol. Sci. 2007, 28(7):316-325.
7. Arias H.R. Localization of agonist and competitive antagonist binding sites on nicotinic acetylcholine receptors. Neurochem. Int. 2000, 36(7):595-645.
8. Turk T., Macek P., Suput D. Inhibition of acetylcholinesterase by a pseudozoanthoxanthin-like compound isolated from the zoanthid Parazoanthus axinellae (O. Schmidt). Toxicon 1995, 33(2):133-142.
9. Sepcic K., Turk T., Macek P. Anticholinesterase activity of the fluorescent zoanthid pigment, parazoanthoxanthin A. Toxicon 1998, 36(6):937-940.
10. Olivera-Bravo S., Ivorra I., Morales A. The acetylcholinesterase inhibitor BW284c51 is a potent blocker of Torpedo nicotinic AchRs incorporated into the Xenopus oocyte membrane. Br. J. Pharmacol. 2005, 144(1):88-97.
11. Canti C., Bodas E., Marsal J., Solsona C. Tacrine and physostigmine block nicotinic receptors in Xenopus oocytes injected with Torpedo electroplaque membranes. Eur. J. Pharmacol. 1998, 363(2-3):197-202.
12. Marco-Contelles J., do Carmo Carreiras M., Rodriguez C., Villarroya M., Garcia A.G. Synthesis and pharmacology of galantamine. Chem. Rev. 2006, 106(1):116-133.
13. Ying-zi X., Yakushijin K., Horne D.A. Biomimetic transformations of 2-aminoimidazole into zoanthoxanthins: exposing a potential biogenic missing link. Tetrahedron Lett. 1992, 33(31):4385-4388.
14. Krieger F., Mourot A., Araoz R., Kotzyba-Hibert F., Molgo J., Bamberg E., Goeldner M. Fluorescent agonists for the Torpedo nicotinic acetylcholine receptor. Chembiochem 2008, 9(7):1146-1153.
15. Texido L., Ros E., Martin-Satue M., Lopez S., Aleu J., Marsal J., Solsona C. Effect of galantamine on the human alpha7 neuronal nicotinic acetylcholine receptor, the Torpedo nicotinic acetylcholine receptor and spontaneous cholinergic synaptic activity. Br. J. Pharmacol. 2005, 145(5):672-678.
16. Olivera-Bravo S., Ivorra I., Morales A. Diverse inhibitory actions of quaternary ammonium cholinesterase inhibitors on Torpedo nicotinic ACh receptors transplanted to Xenopus oocytes. Br. J. Pharmacol. 2007, 151(8):1280-1292.
17. Morales A., Aleu J., Ivorra I., Ferragut J.A., Gonzalez-Ros J.M., Miledi R. Incorporation of reconstituted acetylcholine receptors from Torpedo into the Xenopus oocyte membrane. Proc. Natl. Acad. Sci. U.S.A. 1995, 92(18):8468-8472.
18. Akk G., Steinbach J.H. Galantamine activates muscle-type nicotinic acetylcholine receptors without binding to the acetylcholine-binding site. J. Neurosci. 2005, 25(8):1992-2001.
19. Zwart R., van Kleef R.G., Gotti C., Smulders C.J., Vijverberg H.P. Competitive potentiation of acetylcholine effects on neuronal nicotinic receptors by acetylcholinesterase-inhibiting drugs. J. Neurochem. 2000, 75(6):2492-2500.
20. Prince R.J., Pennington R.A., Sine S.M. Mechanism of tacrine block at adult human muscle nicotinic acetylcholine receptors. J. Gen. Physiol. 2002, 120(3):369-393.
21. Takada-Takatori Y., Kume T., Sugimoto M., Katsuki H., Sugimoto H., Akaike A. Acetylcholinesterase inhibitors used in treatment of Alzheimer's disease prevent glutamate neurotoxicity via nicotinic acetylcholine receptors and phosphatidylinositol 3-kinase cascade. Neuropharmacology 2006, 51(3):474-486.
22. Bufler J., Wilhelm R., Parnas H., Franke C., Dudel J. Open channel and competitive block of the embryonic form of the nicotinic receptor of mouse myotubes by (+)-tubocurarine. J. Physiol. (Lond.) 1996, 495(Pt 1):83-95.
23. Colquhoun D., Dreyer F., Sheridan R.E. The actions of tubocurarine at the frog neuromuscular junction. J. Physiol. (Lond.) 1979, 293:247-284.